Siegler; Karl-Ernst

Patent Applications and Registrations

Patent applications and USPTO patent grants for Siegler; Karl-Ernst.The latest application filed is for "association of edg5 polymorphism v286a with type ii diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof".

Company Profile

0.9.10

Siegler; Karl-Ernst - Ludwigshafen DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism Grant 8,420,321 - Kozian , et al. April 16, 2	2013-04-16
Association Of Edg5 Polymorphism V286a With Type Ii Diabetes Mellitus And Venous Thrombosis/pulmonary Embolism And The Use Thereof App 20120208200 - KOZIAN; Detlef ; et al.	2012-08-16
Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof Grant 8,198,022 - Kozian , et al. June 12, 2	2012-06-12
Use of a GIP promoter polymorphism Grant 8,084,198 - Kozian , et al. December 27, 2	2011-12-27
METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM App 20110223628 - KOZIAN; Detlef ; et al.	2011-09-15
Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism Grant 7,985,562 - Kozian , et al. July 26, 2	2011-07-26
Association Of Edg5 Polymorphism V286a With Type Ii Diabetes Mellitus And Venous Thrombosis/pulmonary Embolism And The Use Thereof App 20110104704 - Kozian; Detlef ; et al.	2011-05-05
Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders Grant 7,892,744 - Kozian , et al. February 22, 2	2011-02-22
Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof Grant 7,888,020 - Kozian , et al. February 15, 2	2011-02-15
Analysis And Use Of Par1 Polymorphisms For Evaluating The Risk Of Cardiovascular Disease App 20100221714 - KOZIAN; Detlef ; et al.	2010-09-02
Use Of Adamts4 Gene And Protein Polymorphisms App 20100062431 - Kozian; Detlef ; et al.	2010-03-11
METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM App 20090239237 - KOZIAN; Detlef ; et al.	2009-09-24
Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism Grant 7,560,290 - Kozian , et al. July 14, 2	2009-07-14
Use of a Gip Promoter Polymorphism App 20080312098 - Kozian; Detlef ; et al.	2008-12-18
Association of Protein Polymorphisms With Coronary Heart Disease App 20070292859 - Kozian; Detlef ; et al.	2007-12-20
Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof Grant 7,262,273 - Kozian , et al. August 28, 2	2007-08-28
Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-IIe347 polymorphism App 20060040296 - Kozian; Detlef ; et al.	2006-02-23
Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders App 20050019795 - Kozian, Detlef ; et al.	2005-01-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.